Zobrazeno 1 - 10
of 22
pro vyhledávání: '"E. V. Karabina"'
Autor:
A. A. Rumyantsev, A. E. Protasova, M. Yu. Sheremet, A. Yu. Goryainova, M. V. Volkonskiy, A. G. Kedrova, S. V. Kuzmicheva, O. N. Aymamedova, Kh. S. Musaeva, S. M. Soroka, O. V. Romanchuk, V. N. Orlova, N. G. Graft, M. R. Ibragimova, Yu. I. Merzlikina, L. V. Stepura, L. B. Tatulova, A. A. Abasova, A. A. Akopyan, E. V. Arsenyeva, Yu. V. Vasilyeva, A. V. Belonogov, L. V. Krivolapova, A. A. Bobryshev, D. Yu. Vovk, I. A. Luev, N. R. Abidova, R. S. Zhikhorev, T. A. Zhelezkova, T. T. Grigoryan, T. A. Makarkina, V. A. Ekimov, A. V. Zhizhina, E. V. Karabina, O. A. Kuchevskaya, V. M. Filippova, T. A. Linchenko, A. A. Lisaeva, A. N. Fedorova, K. S. Maystrenko, E. V. Markizova, E. V. Kogay, E. P. Krasnorutskaya, M. E. Popova, Yu. Yu. Pchelin, R. A. Ryanzhina, D. B. Sidorov, E. B. Shakhnovich, S. M. Alekseev, M. V. Zinkevich, I. O. Belogortsev, V. A. Chubenko, V. M. Moiseenko, N. Kh. Abduloeva, A. A. Lebedinets, L. V. Strakh, L. K. Semenov, M. B. Bolieva, F. Z. Aydaeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 4, Pp 104-113 (2024)
Aim. To assess the efficacy and safety of lenvatinib and pembrolizumab for the treatment of mismatch repair-proficient endometrial cancer (EC) in routine clinical practice in Russia.Materials and methods. This multicenter, retrospective, cohort study
Externí odkaz:
https://doaj.org/article/b505b127d35446839d80501e03b80b14
Publikováno v:
Креативная хирургия и онкология, Vol 12, Iss 2, Pp 164-171 (2022)
The off-label use of medicines is a routine clinical practice of oncology, especially in malignant-tumour patients with no treatment alternatives left when registered-drug options have been exhausted or standard therapies reveal contraindications. Th
Externí odkaz:
https://doaj.org/article/c3e8a83e0fd6422b816023ec39d205af
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, G. Z. Mukhametshina, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, O. V. Sekhina, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, M. A. Lyadova, A. A. Tryakin, S. A. Tyulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 11, Iss 3-4, Pp 11-17 (2022)
Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patient
Externí odkaz:
https://doaj.org/article/2d03f1018a45430f833cbda769ac5776
Autor:
E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 36-46 (2021)
Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the opti
Externí odkaz:
https://doaj.org/article/ddfb182fcf6247f0b4a7bd188e53d850
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, L. V. Bolotina, F. V. Moiseenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseenko, А. А. Meshcheryakov, E. V. Artamonova, I. A. Pokataev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, A. A. Tryakin, S. A. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 2, Pp 29-37 (2019)
Objective: to identify factors associated with efficacy of an aflibercept-chemotherapy combination in patients with metastatic colon cancer.Materials and methods. This retrospective multicenter study was conducted in 20 clinics from 15 regions of the
Externí odkaz:
https://doaj.org/article/743bdd161bd0481991ada713bfba7dbc
Publikováno v:
Успехи молекулярной онкологии, Vol 5, Iss 3, Pp 17-24 (2018)
The prospects of treatment strategies for patients with non-small cell lung cancer (NSCLC) featuring the acquired resistance to tyrosine kinase inhibitors, not associated with the Т790М mutation, are quite vast from a scientific point of view, but
Externí odkaz:
https://doaj.org/article/02d0841490834e8c87aaf720adfcf981
Publikováno v:
Современная онкология, Vol 20, Iss 3, Pp 10-18 (2018)
Understanding the mechanisms of acquired resistance to tyrosine kinase inhibitors is important for clinicians from the perspective of the possibility of forming more effective options for the second and subsequent treatment of non-small cell lung can
Externí odkaz:
https://doaj.org/article/231c9841778448ba9fb15a69ce4630cb
Publikováno v:
Медицинский совет, Vol 0, Iss 14, Pp 46-55 (2017)
A reasonable strategy for drug therapy of non-small-cell lung cancer (NSCLC) with activating mutations of EGFR is the use of tyrosine kinase inhibitors (TKI) in front-line therapy, providing a two-fold increase in life expectancy for patients with me
Externí odkaz:
https://doaj.org/article/9dbd6436ce584e55b23a0a67c38d70b6
Autor:
L V Bolotina, L V Manziuk, V A Gorbunova, E I Kovalenko, G Z Mukhametshina, A I Khasanova, L Yu Vladimirova, I S Mitashok, E P Prokofyeva, I V Evstigneeva, I I Andreyashkina, N A Abramova, I L Popova, E V Karabina, A A Teterich, E A Gaysina, V A Chubenko, S V Limareva, N M Tikhanovskaya, A E Storozhakova, N Yu Samaneva, Ya V Svetitskaya, T A Snezhko, E A Kalabanova
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 27-32 (2016)
The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of th
Externí odkaz:
https://doaj.org/article/02544f99d49748aabf8218f99df2b907
Autor:
E V Karabina, L G Zhukova
Publikováno v:
Современная онкология, Vol 18, Iss 2, Pp 34-38 (2016)
Treatment of patients with metastatic breast cancer (BC) with a triple-negative phenotype represents the most difficult challenge for clinicians. The optimal chemotherapy regimens for triple-negative BC (TNBC) have not been determined for a long time
Externí odkaz:
https://doaj.org/article/1040ab81d1624f6cb5c5011543a949e2